Author:
Zhdanava Maryia,Kachroo Sumesh,Boonmak Porpong,Burbage Sabree,Shah Aditi,Korsiak Jill,Lefebvre Patrick,Kerner Caroline,Pilon Dominic
Funder
Janssen Scientific Affairs, LLC, a Johnson & Johnson Company
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Aslam N, Lo SW, Sikafi R, et al. A review of the therapeutic management of ulcerative colitis. Therap Adv Gastroenterol. 2022;15:17562848221138160. https://doi.org/10.1177/17562848221138160.
2. Ye Y, Manne S, Treem WR, et al. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007–2016. Inflamm Bowel Dis. 2020;26(4):619–25. https://doi.org/10.1093/ibd/izz182.
3. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413. https://doi.org/10.14309/ajg.0000000000000152.
4. AbbVie Inc. RINVOQ® (upadacitinib) Highlights of Prescribing Information 2023. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf. Accessed 9 Feb 2024.
5. Bristol Myers Squibb Company. ZEPOSIA® (ozanimod) Highlights of Prescribing Information 2023. https://packageinserts.bms.com/pi/pi_zeposia.pdf. Accessed 9 Feb 2024.